PubRank

Richard B S Roden

Author PubWeight™ 70.39‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 CD80 in immune suppression by mouse ovarian carcinoma-associated Gr-1+CD11b+ myeloid cells. Cancer Res 2006 2.92
2 A protective and broadly cross-neutralizing epitope of human papillomavirus L2. J Virol 2007 2.36
3 Cross-neutralization of cutaneous and mucosal Papillomavirus types with anti-sera to the amino terminus of L2. Virology 2005 2.31
4 Mechanisms of human papillomavirus type 16 neutralization by l2 cross-neutralizing and l1 type-specific antibodies. J Virol 2008 2.22
5 Identification of molecular pathway aberrations in uterine serous carcinoma by genome-wide analyses. J Natl Cancer Inst 2012 2.09
6 Protection against heterologous human papillomavirus challenge by a synthetic lipopeptide vaccine containing a broadly cross-neutralizing epitope of L2. Proc Natl Acad Sci U S A 2008 2.00
7 Concatenated multitype L2 fusion proteins as candidate prophylactic pan-human papillomavirus vaccines. J Natl Cancer Inst 2009 1.95
8 Protection of rabbits against challenge with rabbit papillomaviruses by immunization with the N terminus of human papillomavirus type 16 minor capsid antigen L2. J Virol 2007 1.70
9 Cell surface-binding motifs of L2 that facilitate papillomavirus infection. J Virol 2003 1.68
10 Interaction of tSNARE syntaxin 18 with the papillomavirus minor capsid protein mediates infection. J Virol 2005 1.61
11 Detection of somatic TP53 mutations in tampons of patients with high-grade serous ovarian cancer. Obstet Gynecol 2014 1.46
12 Ubiquitin-proteasome system stress sensitizes ovarian cancer to proteasome inhibitor-induced apoptosis. Cancer Res 2006 1.41
13 Ubiquitin proteasome system stress underlies synergistic killing of ovarian cancer cells by bortezomib and a novel HDAC6 inhibitor. Clin Cancer Res 2008 1.33
14 Delivery of telomerase reverse transcriptase small interfering RNA in complex with positively charged single-walled carbon nanotubes suppresses tumor growth. Clin Cancer Res 2006 1.28
15 Papillomavirus-like particles stimulate murine bone marrow-derived dendritic cells to produce alpha interferon and Th1 immune responses via MyD88. J Virol 2004 1.27
16 Interaction of L2 with beta-actin directs intracellular transport of papillomavirus and infection. J Biol Chem 2003 1.27
17 Chemotherapy acts as an adjuvant to convert the tumor microenvironment into a highly permissive state for vaccination-induced antitumor immunity. Cancer Res 2013 1.27
18 Vaccination of healthy volunteers with human papillomavirus type 16 L2E7E6 fusion protein induces serum antibody that neutralizes across papillomavirus species. Cancer Res 2006 1.26
19 A papillomavirus-like particle (VLP) vaccine displaying HPV16 L2 epitopes induces cross-neutralizing antibodies to HPV11. Vaccine 2006 1.25
20 Tissue-spanning redox gradient-dependent assembly of native human papillomavirus type 16 virions. J Virol 2009 1.18
21 B lymphocyte activation by human papillomavirus-like particles directly induces Ig class switch recombination via TLR4-MyD88. J Immunol 2005 1.16
22 Combination of proteasome and HDAC inhibitors for uterine cervical cancer treatment. Clin Cancer Res 2009 1.14
23 Papillomavirus infection requires gamma secretase. J Virol 2010 1.12
24 Immunotherapy for gynaecological malignancies. Expert Opin Biol Ther 2005 1.10
25 Development of AAVLP(HPV16/31L2) particles as broadly protective HPV vaccine candidate. PLoS One 2012 1.08
26 L2, the minor capsid protein of papillomavirus. Virology 2013 1.07
27 The positively charged termini of L2 minor capsid protein required for bovine papillomavirus infection function separately in nuclear import and DNA binding. J Virol 2004 1.06
28 Application of Bayesian modeling of autologous antibody responses against ovarian tumor-associated antigens to cancer detection. Cancer Res 2006 1.06
29 Vaccination with HPV16 L2E6E7 fusion protein in GPI-0100 adjuvant elicits protective humoral and cell-mediated immunity. Vaccine 2008 1.05
30 Vaccination with multimeric L2 fusion protein and L1 VLP or capsomeres to broaden protection against HPV infection. Vaccine 2010 1.05
31 Developing vaccines against minor capsid antigen L2 to prevent papillomavirus infection. Immunol Cell Biol 2009 1.02
32 Papillomavirus capsid mutation to escape dendritic cell-dependent innate immunity in cervical cancer. J Virol 2005 1.00
33 Papillomavirus prophylactic vaccines: established successes, new approaches. J Virol 2009 1.00
34 Photonic approach to the selective inactivation of viruses with a near-infrared subpicosecond fiber laser. J Biomed Opt 2010 0.99
35 p53 autoantibodies, cytokine levels and ovarian carcinogenesis. Gynecol Oncol 2009 0.99
36 Comparison of candidate serologic markers for type I and type II ovarian cancer. Gynecol Oncol 2011 0.97
37 Myosin II co-chaperone general cell UNC-45 overexpression is associated with ovarian cancer, rapid proliferation, and motility. Am J Pathol 2007 0.96
38 Personalized chemotherapy profiling using cancer cell lines from selectable mice. Clin Cancer Res 2013 0.96
39 Identification of glycoproteins associated with different histological subtypes of ovarian tumors using quantitative glycoproteomics. Proteomics 2011 0.96
40 Optimization of multimeric human papillomavirus L2 vaccines. PLoS One 2013 0.95
41 Enhanced cancer radiotherapy through immunosuppressive stromal cell destruction in tumors. Clin Cancer Res 2013 0.92
42 Expression pattern and subcellular localization of human papillomavirus minor capsid protein L2. Am J Pathol 2008 0.92
43 Phylogenetic considerations in designing a broadly protective multimeric L2 vaccine. J Virol 2013 0.92
44 Prevention of cancer by prophylactic human papillomavirus vaccines. Curr Opin Immunol 2010 0.92
45 Virus-like particles for the prevention of human papillomavirus-associated malignancies. Expert Rev Vaccines 2013 0.90
46 Murine skin and vaginal mucosa are similarly susceptible to infection by pseudovirions of different papillomavirus classifications and species. Virology 2012 0.89
47 α,β-Unsaturated carbonyl system of chalcone-based derivatives is responsible for broad inhibition of proteasomal activity and preferential killing of human papilloma virus (HPV) positive cervical cancer cells. J Med Chem 2010 0.88
48 Stressing the ubiquitin-proteasome system without 20S proteolytic inhibition selectively kills cervical cancer cells. PLoS One 2011 0.87
49 The future of vaccines for cervical cancer. Gynecol Oncol 2008 0.87
50 Human papillomavirus vaccines for the prevention and treatment of cervical cancer. Curr Opin Investig Drugs 2004 0.85
51 Immunohistochemical detection of human papillomavirus capsid proteins L1 and L2 in squamous intraepithelial lesions: potential utility in diagnosis and management. Mod Pathol 2012 0.85
52 Human papillomavirus type-16 virus-like particles activate complementary defense responses in key dendritic cell subpopulations. J Immunol 2004 0.85
53 The high risk HPV16 L2 minor capsid protein has multiple transport signals that mediate its nucleocytoplasmic traffic. Virology 2011 0.85
54 Multivalent human papillomavirus l1 DNA vaccination utilizing electroporation. PLoS One 2013 0.84
55 HPV pseudovirions as DNA delivery vehicles. Ther Deliv 2011 0.83
56 Capsomer vaccines protect mice from vaginal challenge with human papillomavirus. PLoS One 2011 0.83
57 A multimeric L2 vaccine for prevention of animal papillomavirus infections. Virology 2011 0.76
58 Vaccines against human papillomavirus. Front Biosci 2007 0.76
59 GATA-3 expression in trophoblastic tissues: an immunohistochemical study of 445 cases, including diagnostic utility. Am J Surg Pathol 2015 0.75